NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Last trade$11.14
Day change-$0.16 (-1.42%)
Day range$11.10 – $12.94
Volume481,312
Market cap$1.32B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.32B
Price / earnings
—
Price / book
3.77×
Price / sales
1.82×
EV / sales
1.96×
EV / EBITDA
-13.22×
Profitability
Earnings per share
-$1.04
Return on assets
-14.69%
Return on equity
-34.72%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.56×
Current ratio
2.49×
Quick ratio
2.34×
Cash ratio
0.36×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.61M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NVCR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$193.4M
$183.58M
$174.06M
$174.35M
$167.2M
$158.81M
$154.99M
$161.27M
Cost of revenue
$44.53M
$41.11M
$38.93M
$42.16M
$44.73M
$41.47M
$38.52M
$33.47M
Gross profit
$148.87M
$142.48M
$135.13M
$132.19M
$122.48M
$117.33M
$116.47M
$127.8M
Selling, general and administrative
$96.94M
$101.59M
$144.21M
$111.68M
$104.47M
$101.02M
$100.56M
$139.89M
Research and development
$58.1M
$51.45M
$58.34M
$60.91M
$54.03M
$55.83M
$53.78M
$51.21M
Total operating expenses
$155.04M
$153.04M
$202.55M
$172.59M
$158.5M
$156.85M
$154.34M
$191.1M
Operating income
-$6.17M
-$10.56M
-$67.42M
-$40.39M
-$36.02M
-$39.52M
-$37.87M
-$63.3M
Interest expense
-$1.71M
-$1.89M
$0
-$561K
$6M
$4.54M
$0
$0
Income before taxes
-$7.88M
-$12.45M
-$69.26M
-$40.95M
-$30.02M
-$34.98M
-$30.3M
-$55.21M
Income taxes
$2.56M
$3.21M
$1.88M
-$16.46M
$7.25M
$5.16M
$4.02M
$10.72M
Net income
-$10.44M
-$15.66M
-$71.14M
-$24.5M
-$37.27M
-$40.14M
-$34.32M
-$65.92M
Net income attributable to common shareholders
-$10.44M
-$15.66M
-$71.14M
-$24.5M
-$37.27M
-$40.14M
-$34.32M
-$65.92M
EBITDA
-$1.76M
-$6.26M
-$63.3M
-$36.18M
-$32.36M
-$36.08M
-$34.54M
-$60.2M
Basic earnings per share
-$0.09
-$0.13
-$0.62
-$0.22
-$0.33
-$0.36
-$0.31
-$0.61
Diluted earnings per share
-$0.09
-$0.13
-$0.62
-$0.22
-$0.33
-$0.36
-$0.31
-$0.61
Recent news
Company coverage with links to the original publishers.
The FDA issued a not approvable letter for NovoCure's Optune Mya device for treating lung cancer brain metastases, citing uncertainty around clinical benefit despite no safety concerns. The rejection compounds investor concerns following lackluster Q3 earnings and competition from Revolution Medicines' newly approved Rasonque pill for pancreatic cancer. NovoCure's stock fell 7.34% on the news, and the analyst recommends against investing in the beaten-down equity.
NovoCure reported record Q3 2026 revenue of $193 million with 16% year-over-year growth, achieving adjusted EBITDA positivity. The company is expanding internationally with Japan emerging as its second-largest market, though pancreatic cancer product Optune Pax faces headwinds from competing drug diraxonrasib. Full-year guidance was raised to $736-743 million.
Novocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no material financial impact is expected. NVCR shares rose 3.2% since the September 1 disclosure.
Broadcom's disappointing AI-chip guidance triggered a semiconductor sell-off, dragging down the Nasdaq while the S&P 500 and Dow Jones gained on sector rotation and value tailwinds. Healthcare stocks rallied with Eli Lilly and NovoCure posting strong gains. The pullback raises questions about AI stock valuations and whether the semiconductor sector's 170% annual rally is cooling.
The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.